Skip to main content
Veterinary Medicines

Baycox Multi 50 mg/ml oral suspension for Cattle, Pigs and Sheep

Authorised
  • Toltrazuril

Product identification

Medicine name:
Baycox Multi 50 mg/ml oral suspension for Cattle, Pigs and Sheep
Baycoxine vet 50 mg/ml Oral suspension
Active substance:
  • Toltrazuril
Target species:
  • Cattle
  • Sheep
  • Pig
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Toltrazuril
    50.00
    milligram(s)
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Oral suspension
Withdrawal period by route of administration:
  • Oral use
    • Cattle
      • Meat and offal
        63
        day
    • Sheep
      • Meat and offal
        42
        day
    • Pig
      • Meat and offal
        77
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QP51AJ01
Authorisation status:
  • Valid
Authorised in:
  • Sweden
Available in:
  • Sweden
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Marketing authorisation holder:
  • Elanco Animal Health GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • KVP Pharma+Veterinär Produkte GmbH
Responsible authority:
  • Swedish Medical Products Agency
Authorisation number:
  • 53821
Date of authorisation status change:
Reference member state:
  • Ireland
Procedure number:
  • IE/V/0360/001
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Italy
  • Latvia
  • Lithuania
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

English (PDF)
Published on: 11/02/2022
Download
Swedish (PDF)
Published on: 26/04/2022

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Swedish (PDF)
Published on: 26/04/2022
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."